• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

ICER's Gaze Turns to COVID Vaccine, Treatment Prices


The Institute for Clinical and Economic Review (ICER) is jumping into the fray of putting a price on what the world is waiting for — a safe, effective COVID-19 vaccine.

It published a white paper yesterday titled "Alternative Policies for Pricing Novel Vaccines and Drug Therapies for COVID-19" (treatment is mentioned but the focus is on vaccines).

Later this month and in early August, the Boston-based cost-effectiveness group is hosting a three-part online colloquium on the same topic. Peter Bach, Steve Miller, David Mitchell, and Aaron Kesselheim are scheduled to participate.

The white paper, written by Steven Pearson, ICER president, and Sarah Emond, the group's executive vice president, outlines six possible approaches to pricing a vaccine: unrestricted (which the white paper says is the status quo), cost-recovery, value-based, monetary prizes, compulsory licensing, and advanced market commitments.

Price has already entered the picture for antiviral treatments of COVID-19. Earlier this week, Gilead priced a five-day course of its antiviral, remdesivir, at $3,120 for patients with private insurance. Based on several assumptions, including a mortality benefit, an ICER report had benchmarked the price at $4,580-$5,080, although if remdesivir is used with dexamethasone, the ICER said benchmark should be dropped to $2,520-$2,800. In a prepared after Gilead announced the price, ICER said it wa a responsibe decision and "a promising sign for pricing decisions of other treatments for COVID-19 on the horizon.

Related Videos
Video 3 - "In-Office Procedures, Over-the-Counter Options, Treatment Delays, and Costs"
Video 6 - "Safety Analysis and Interpreting Results from MAJIC-PV"
Video 5 - "Key Findings from MAJIC-PV"
Video 2 - "Traditional Treatment of Demodex Blepharitis, FDA approval, and Lotilaner Ophthalmic Solution, 0.25%"
Gabriela Hobbs, MD, an expert on polycythemia vera
Gabriela Hobbs, MD, and Timothy Mok, PharmD, BCPS, BCOP
Video 1 - "Demodex Blepharitis: Prevalence, Symptoms, Quality of Life Impact, and Diagnosis"
Video 2 - "The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance"
Video 1 - "Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera"
Related Content
© 2024 MJH Life Sciences

All rights reserved.